Seattle Genetics Poised For Big Breast Cancer Launch On Positive Tucatinib Data
Executive Summary
The company expects to file an NDA for tucatinib in the first quarter after a pivotal trial showed a significant improvement in PFS and OS for patients with advanced or metastatic HER2-positive breast cancer, including those with brain metastases.
You may also be interested in...
Twice As Nice: Seattle Genetics, Merck & Co. Partner On Two Cancer Drugs
Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.
Seattle Genetics Win Early US FDA Approval For Tukysa, Plans Rapid Launch
Tucatinib, approved for advanced unresectable or metastatic HER2-positive breast cancer, has a list price of $18,500 per month or $111,000 for a full course. Doctors can order the drug immediately.
Data For Two HER2-Positive Breast Cancer Drugs Impress, Including On Overall Survival
AstraZeneca/Daiichi Sankyo and Seattle Genetics presented exciting data at SABCS on drugs that extended survival in patients who had exhausted most treatment options.